Pacira BioSciences
PCRX
276 hedge funds and large institutions have $3.04B invested in Pacira BioSciences in 2021 Q4 according to their latest regulatory filings, with 46 funds opening new positions, 105 increasing their positions, 82 reducing their positions, and 26 closing their positions.
77% more first-time investments, than exits
New positions opened: 46 | Existing positions closed: 26
33% more funds holding in top 10
Funds holding in top 10: 3 → 4 (+1)
28% more repeat investments, than reductions
Existing positions increased: 105 | Existing positions reduced: 82
11% more capital invested
Capital invested by funds: $2.75B → $3.04B (+$298M)
7% more funds holding
Funds holding: 259 → 276 (+17)
3.11% more ownership
Funds ownership: 110.52% → 113.63% (+3.1%)
67% less call options, than puts
Call options by funds: $1.67M | Put options by funds: $5.08M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PC
Paulson & Co
New York
|
+$24.6M |
| 2 |
AC
Armistice Capital
New York
|
+$20.7M |
| 3 |
Baillie Gifford & Co
Edinburgh,
United Kingdom
|
+$14.7M |
| 4 |
Marshall Wace
London,
United Kingdom
|
+$10.5M |
| 5 |
HCM
Hodges Capital Management
Dallas,
Texas
|
+$9.26M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DM
Deerfield Management
New York
|
-$20.5M |
| 2 |
Wells Fargo
San Francisco,
California
|
-$18M |
| 3 |
NPIC
Neumeier Poma Investment Counsel
Carmel,
California
|
-$16.2M |
| 4 |
Goldman Sachs
New York
|
-$14.3M |
| 5 |
TA
Tamarack Advisers
Carlsbad,
California
|
-$7.44M |
PCRX Hedge Fund Activity: Q4 2021 in Review
276 of the 6,498 institutional investors tracked by Wall St. Rank reported a position in Pacira BioSciences (PCRX) for Q4 2021, worth a combined $3.04B — up 11% from $2.75B a quarter earlier.
Buyers outnumbered sellers: 46 funds opened new PCRX positions and 26 closed out — a net gain of 20 holders — while 105 added to existing stakes and 82 trimmed.
The largest buyer was Paulson & Co, adding an estimated $24.6M. The largest seller was Deerfield Management, cutting an estimated $20.5M.
- 276 institutional investors held Pacira BioSciences (PCRX) as of Q4 2021, up from 259 in Q3 2021.
- Funds reported $3.04B of Pacira BioSciences stock for Q4 2021, up 11% quarter-over-quarter.
- 46 funds opened new Pacira BioSciences positions in Q4 2021 and 26 closed out, a net change of +20 holders.
- The largest Pacira BioSciences buyer in Q4 2021 was Paulson & Co, an estimated $24.6M added.
- The largest Pacira BioSciences seller in Q4 2021 was Deerfield Management, an estimated $20.5M sold.
Based on aggregated 13F filings for Q4 2021.